NYXOAH SA (NYXH) Stock Fundamental Analysis
USA - NASDAQ:NYXH - BE0974358906 - Common Stock
4.917 USD
-0.1 (-2.05%)
Taking everything into account, NYXH scores 2 out of 10 in our fundamental rating. NYXH was compared to 189 industry peers in the Health Care Equipment & Supplies industry. NYXH may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NYXH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year NYXH has reported negative net income.
In the past year NYXH has reported a negative cash flow from operations.
NYXH had negative earnings in each of the past 5 years.
NYXH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -66.28%, NYXH is doing worse than 71.96% of the companies in the same industry.
With a Return On Equity value of -105.18%, NYXH is not doing good in the industry: 64.02% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.28% | ||
| ROE | -105.18% | ||
| ROIC | N/A |
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 65.27%, NYXH is in the better half of the industry, outperforming 69.84% of the companies in the same industry.
NYXH's Gross Margin has been stable in the last couple of years.
NYXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
NYXH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NYXH has been increased compared to 5 years ago.
Compared to 1 year ago, NYXH has a worse debt to assets ratio.
2.2 Solvency
NYXH has an Altman-Z score of -2.47. This is a bad value and indicates that NYXH is not financially healthy and even has some risk of bankruptcy.
NYXH's Altman-Z score of -2.47 is on the low side compared to the rest of the industry. NYXH is outperformed by 62.43% of its industry peers.
A Debt/Equity ratio of 0.29 indicates that NYXH is not too dependend on debt financing.
NYXH's Debt to Equity ratio of 0.29 is in line compared to the rest of the industry. NYXH outperforms 51.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.47 |
ROIC/WACCN/A
WACC7.4%
2.3 Liquidity
A Current Ratio of 2.63 indicates that NYXH has no problem at all paying its short term obligations.
NYXH has a Current ratio (2.63) which is comparable to the rest of the industry.
A Quick Ratio of 2.38 indicates that NYXH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.38, NYXH is in line with its industry, outperforming 58.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.63 | ||
| Quick Ratio | 2.38 |
3. Growth
3.1 Past
NYXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.57%.
The Revenue has been growing slightly by 2.94% in the past year.
NYXH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.42% yearly.
EPS 1Y (TTM)-41.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.74%
Revenue 1Y (TTM)2.94%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%73.8%
3.2 Future
The Earnings Per Share is expected to grow by 3.45% on average over the next years.
NYXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 117.81% yearly.
EPS Next Y-24.84%
EPS Next 2Y-8.36%
EPS Next 3Y3.45%
EPS Next 5YN/A
Revenue Next Year57.01%
Revenue Next 2Y156.82%
Revenue Next 3Y141.05%
Revenue Next 5Y117.81%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NYXH. In the last year negative earnings were reported.
Also next year NYXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.36%
EPS Next 3Y3.45%
5. Dividend
5.1 Amount
NYXH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NYXH (11/7/2025, 8:02:50 PM)
4.917
-0.1 (-2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners22.74%
Inst Owner Change0.85%
Ins Owners22.07%
Ins Owner ChangeN/A
Market Cap184.04M
Revenue(TTM)4.93M
Net Income(TTM)-77.20M
Analysts81.43
Price Target13.89 (182.49%)
Short Float %1.2%
Short Ratio3.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.5%
Min EPS beat(2)-22.16%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-4.61%
Min EPS beat(4)-22.16%
Max EPS beat(4)5.16%
EPS beat(8)6
Avg EPS beat(8)2.91%
EPS beat(12)7
Avg EPS beat(12)-7.28%
EPS beat(16)9
Avg EPS beat(16)-4.34%
Revenue beat(2)0
Avg Revenue beat(2)-19.91%
Min Revenue beat(2)-38.43%
Max Revenue beat(2)-1.4%
Revenue beat(4)0
Avg Revenue beat(4)-21.65%
Min Revenue beat(4)-38.43%
Max Revenue beat(4)-1.4%
Revenue beat(8)1
Avg Revenue beat(8)-22.06%
Revenue beat(12)1
Avg Revenue beat(12)-32.46%
Revenue beat(16)1
Avg Revenue beat(16)-37%
PT rev (1m)-8.44%
PT rev (3m)-6.53%
EPS NQ rev (1m)-0.57%
EPS NQ rev (3m)-7.05%
EPS NY rev (1m)-5.7%
EPS NY rev (3m)-20.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-18.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-39.97%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 32.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.17 | ||
| P/tB | 7.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.44
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-1.93
FCFYN/A
OCF(TTM)-1.88
OCFYN/A
SpS0.15
BVpS2.27
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.28% | ||
| ROE | -105.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.27% | ||
| FCFM | N/A |
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 49.33% | ||
| Cap/Sales | 29.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.63 | ||
| Quick Ratio | 2.38 | ||
| Altman-Z | -2.47 |
F-Score3
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.74%
EPS Next Y-24.84%
EPS Next 2Y-8.36%
EPS Next 3Y3.45%
EPS Next 5YN/A
Revenue 1Y (TTM)2.94%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%73.8%
Revenue Next Year57.01%
Revenue Next 2Y156.82%
Revenue Next 3Y141.05%
Revenue Next 5Y117.81%
EBIT growth 1Y-55.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.6%
EBIT Next 3Y-16.06%
EBIT Next 5Y11.04%
FCF growth 1Y-45.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.67%
OCF growth 3YN/A
OCF growth 5YN/A
NYXOAH SA / NYXH FAQ
What is the fundamental rating for NYXH stock?
ChartMill assigns a fundamental rating of 2 / 10 to NYXH.
What is the valuation status for NYXH stock?
ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH). This can be considered as Overvalued.
Can you provide the profitability details for NYXOAH SA?
NYXOAH SA (NYXH) has a profitability rating of 1 / 10.